Compare PTLO & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTLO | SABS |
|---|---|---|
| Founded | 1963 | 2014 |
| Country | United States | United States |
| Employees | N/A | 86 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.5M | 288.8M |
| IPO Year | 2021 | N/A |
| Metric | PTLO | SABS |
|---|---|---|
| Price | $4.18 | $3.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $8.06 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.5M | 797.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $732,066,000.00 | N/A |
| Revenue This Year | $9.02 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $3.78 | $1.67 |
| 52 Week High | $11.82 | $6.60 |
| Indicator | PTLO | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 60.17 |
| Support Level | $3.79 | $3.48 |
| Resistance Level | $4.40 | $4.09 |
| Average True Range (ATR) | 0.22 | 0.24 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 60.25 | 79.12 |
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.